THYROCARE TECHNOLOGIES share price has zoomed 4% and is presently trading at Rs 860.0.
Meanwhile, the BSE HEALTHCARE index is at 44,785.5 (up 0.1%).
Among the top gainers in the BSE HEALTHCARE index today are HIKAL CHEMIC (up 3.4%) and ALEMBIC PHARMA (up 2.5%).
POLY MEDICURE (down 2.1%) and IPCA Labs (down 1.5%) are among the top losers today.
Over the last one year, THYROCARE TECHNOLOGIES has moved up from Rs 570.3 to Rs 860.0, registering a gain of Rs 289.8 (up 50.8%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,166.2 to 44,785.5, registering a gain of 59.0% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 198.7%), Glenmark Pharma (up 124.7%) and SUVEN PHARMACEUTICALS (up 107.1%).
Dear Reader: If You Invest in Midcap Stocks, this is for You
The BSE Sensex is at 81,755.5 (down 0.1%).
The top losers among the BSE Sensex today are M&M (down 1.6%) and Nestle (down 1.6%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.
In the meantime, NSE Nifty is at 25,068.5 . HDFC LIFE INSURANCE and IOC are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 66,166.9 to 81,755.5, registering a gain of 15,588.5 points (up 23.6%).
THYROCARE TECHNOLOGIES net profit grew 41.9% YoY to Rs 243 million for the quarter ended June 2024, compared to a profit of Rs 171 million a year ago. Net sales rose 16.3% to Rs 1,569 million during the period as against Rs 1,349 million in April-June 2023.
For the year ended March 2024, THYROCARE TECHNOLOGIES reported 8.0% increase in net profit to Rs 695 million compared to net profit of Rs 644 million during FY23. Revenue of the company grew 8.6% to Rs 5,719 million during FY24.
The current Price to earnings ratio of THYROCARE TECHNOLOGIES, based on rolling 12 month earnings, stands at 59.7.
Equitymaster requests your view! Post a comment on "THYROCARE TECHNOLOGIES Gains 4%; BSE HEALTHCARE Index Up 0.1%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!